You are here

Home » The professional team » Sastre-Garriga, Jaume

Sastre-Garriga, Jaume

Neurologist. Deputy director of Cemcat

  • Co-chair of the Steering Committee of MAGNIMS
  • Co-editor for Europe of the Multiple Sclerosis Journal
  • Director of Revista de Neurología

Education

Dr. Jaume Sastre-Garriga received his MD at the University of Barcelona and his PhD at the Universitat Autònoma de Barcelona. He trained as a neurologist at the Neurology Department, Vall d’Hebron University Hospital.

Career

From June 2002 to December 2004 he was a awarded a grant from the Spanish Ministry of Health and held a post as a clinical research fellow at the MRI and Neurorehabilitation units, Institute of Neurology, London, under the mentorship of Professor Alan Thompson. In 2004 and 2005 he was awarded by the Spanish Society of Neurology (SEN) the prize for the best Spanish paper in an international neurological journal. From January 2005 to February 2007 Dr. Sastre-Garriga was Medical Director of the neurorehabilitation centres of the MS Foundation in Catalonia. Since March 2007 he works as a clinical neurologist at the Department of Neurology / MS Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital (Barcelona). From 2014 to 2020 Dr. Sastre-Garriga was Member of the Executive Board of RIMS (European network for best practice and research in MS Rehabilitation).

Projects / Lines of Research / Interests

His main interests are magnetic resonance imaging techniques (functional MRI and volumetry) and neurorehabilitation with a special focus on the primary progressive forms of MS, a disease type to which he devoted his PhD research.

Bio

1: Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016 May 19. pii: 1352458516643600. [Epub ahead of print] Review.

2: Comabella M, Sastre-Garriga J, Montalban X. Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. Curr Opin Neurol. 2016 Jun;29(3):254-62.

3: Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS,Banwell B, Montalban X, Barkhof F; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar;15(3):292-303.

4: Pareto D, Sastre-Garriga J, Auger C, Vives-Gilabert Y, Delgado J, Tintoré M, Montalban X, Rovira A. Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis. AJNR Am J Neuroradiol. 2015 Dec;36(12):2270-6.

5: Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X. Predictive value of early brain atrophy on response in patients treated with interferon β. Neurol Neuroimmunol Neuroinflamm. 2015 Jul 2;2(4):e132.

6: Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015Jul;138(Pt 7):1863-74.

7: Sastre-Garriga J, Tur C, Pareto D, Vidal-Jordana A, Auger C, Río J, Huerga E, Tintoré M, Rovira A, Montalban X. Brain atrophy in natalizumab-treated patients:A 3-year follow-up. Mult Scler. 2015 May;21(6):749-56.

8: Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H,Río J, Edo MC, Horga A, Castilló J, Auger C, Huerga E, Rovira A, Montalban X. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 2013 Dec;19(14):1878-86.

9: Sastre-Garriga J, Alonso J, Renom M, Arévalo MJ, González I, Galán I, Montalban X, Rovira A. A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis. Mult Scler. 2011 Apr;17(4):457-67.

10: Sastre-Garriga J, Ingle GT, Rovaris M, Téllez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, DoussetV, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology. 2005 Aug 23;65(4):633-5.

11: Sastre-Garriga J, Ingle GT, Chard DT, Cercignani M, Ramió-Torrentà L, MillerDH, Thompson AJ. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain. 2005 Jun;128(Pt 6):1454-60.

12: Sastre-Garriga J, Reverter JC, Font J, Tintoré M, Espinosa G, Montalban X. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol. 2001 Mar;49(3):408-11. PubMed PMID: 11261519.